Page last updated: 2024-09-03

dansylsarcosine and Diabetic Nephropathies

dansylsarcosine has been researched along with Diabetic Nephropathies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anraku, M; Chuang, VT; Kawai, K; Komatsu, T; Maruyama, T; Otagiri, M; Seo, H; Taguchi, K; Tanaka, R; Urata, Y; Yamasaki, K1

Other Studies

1 other study(ies) available for dansylsarcosine and Diabetic Nephropathies

ArticleYear
Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:2

    Topics: Animals; Binding Sites; Dansyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dimerization; Drug Carriers; Fatty Acids; Fluorescent Dyes; Half-Life; Humans; Hypoglycemic Agents; Male; Maleimides; Permeability; Plasma; Protein Binding; Rats; Rats, Sprague-Dawley; Sarcosine; Serum Albumin; Warfarin

2015